Drug intelligence / Profile preview

SAM-LNP-S

Development stage: Phase 1
Lead developer: National Institute of Allergy and Infectious Diseases
Modality: mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Vaccines & Immunotherapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
Administration: Intramuscular

Overview

SAM-LNP-S is an investigational self-amplifying mRNA (SAM) vaccine delivered via lipid nanoparticles (LNP). It is based on the Venezuelan Equine Encephalitis Virus (VEEV) vector and is designed to express the SARS-CoV-2 Spike protein. It is being evaluated in a Phase 1 clinical trial for its safety, immunogenicity, and reactogenicity as a prophylactic vaccine against SARS-CoV-2 in healthy adults.

Targets

SARS-CoV-2 spike

Beyond the preview

Go deeper on SAM-LNP-S.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SAM-LNP-S.

Explore the full profile